We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 427

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

Still safe the experimental use exception to anticipation

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • July 10 2014

Canada's laws provide a one-year grace period for public disclosures by the applicant (or by a person who obtained knowledge of an invention from the

Patent held invalid for not meeting promise of improved therapeutic profile

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Intellectual property weekly abstract bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 2 2013

The Federal Court of Appeal (FCA) recently upheld the decision of the Trial Judge, holding that one claim of the patent at issue was valid and

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

Generic drug company licensees avoid patented medicines price oversight

  • Osler Hoskin & Harcourt LLP
  • -
  • Canada
  • -
  • June 10 2014

In nearly identical decisions released on May 27, 2014, Sandoz Canada Inc v Canada, 2014 FC 501 (Sandoz) and ratiopharm Inc v Canada, 2014 FC 502

Federal court dismisses notion that patents should be given only one interpretation for all purposes

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • June 19 2014

In a pair of simultaneously released decisions on June 13, 2014, Justice O'Reilly allowed Allergan's applications (the "Applications") prohibiting

Eli Lilly patent for atomoxetine for use in treating ADHD invalid for lack of utility

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • October 19 2010

Novopharm Limited (now known as Teva Canada Limited but hereafter referred to as Novopharm) sought a declaration under s. 60(1) of the Patent Act, R.S.C. 1985, c. P-4 that Eli Lilly and Company’s (Lilly’s) Canadian Patent No. 2,209,735 (the ‘735 Patent) was invalid and void

Federal Court of Appeal refuses to strike pleading of patent infringement ZYMAR (gatifloxacin)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • April 27 2011

On April 14, 2011, the Federal Court of Appeal dismissed an appeal by Apotex Inc. and Apotex Pharmachem Inc. ("Apotex") from an order dismissing its motion to strike the statement of claim filed by Allergan, Inc., Allergan Sales, LLC, Allergan USA, Inc. and Kyorin Pharmaceutical Co., Ltd ("Allergan") in a patent infringement action